GeneDx Sees Unusually High Options Volume (NASDAQ:WGS)

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors bought 6,604 put options on the company. This is an increase of approximately 255% compared to the average daily volume of 1,861 put options.

GeneDx Stock Performance

WGS stock opened at $54.83 on Wednesday. The stock’s 50 day simple moving average is $75.82 and its 200 day simple moving average is $70.91. GeneDx has a 12-month low of $32.21 and a 12-month high of $170.87. The firm has a market cap of $1.64 billion, a P/E ratio of -14.51 and a beta of 2.00. The company has a current ratio of 3.30, a quick ratio of 3.06 and a debt-to-equity ratio of 0.40.

GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.21. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.93%. The firm had revenue of $123.10 million during the quarter, compared to the consensus estimate of $122.93 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. As a group, equities research analysts predict that GeneDx will post -0.41 EPS for the current year.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,728 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at $4,387,081.45. This represents a 7.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $1,025,002.61. Following the completion of the transaction, the chief executive officer directly owned 115,476 shares in the company, valued at approximately $11,271,612.36. The trade was a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 19,206 shares of company stock valued at $1,808,056 in the last three months. 25.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GeneDx

Several institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC boosted its position in GeneDx by 222.7% during the 2nd quarter. First Light Asset Management LLC now owns 783,923 shares of the company’s stock valued at $53,816,000 after purchasing an additional 540,996 shares during the period. Bank of America Corp DE grew its stake in GeneDx by 77.5% during the 1st quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after buying an additional 102,456 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in GeneDx in the first quarter worth $2,177,000. Sumitomo Mitsui Trust Group Inc. increased its position in GeneDx by 65.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 633,457 shares of the company’s stock worth $40,681,000 after buying an additional 251,732 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in GeneDx in the second quarter valued at $4,258,000. 61.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

WGS has been the subject of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. Guggenheim increased their price objective on shares of GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a report on Monday, November 2nd. Wall Street Zen raised shares of GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 9th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $90.14.

View Our Latest Report on WGS

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

  • Positive Sentiment: GeneDx reported third-quarter adjusted earnings of $0.28 per share, above the $0.07 consensus estimate, and revenue of $123.1 million, slightly ahead of expectations. GeneDx Q3 earnings results
  • Neutral Sentiment: Full-year 2026 revenue guidance is $475 million to $490 million, a range that includes the analyst consensus of $481.1 million.
  • Negative Sentiment: Third-quarter exome and genome results rose 25% to 32,134, below the company’s prior growth expectation of at least 29.2%. GeneDx lowered its 2026 volume-growth target to at least 28%, raising concerns about the pace of demand growth. Why GeneDx Holdings stock dropped
  • Negative Sentiment: The company’s fourth-quarter outlook reportedly fell short of analyst expectations, adding to concerns about near-term performance. GeneDx falls as Q4 outlook misses consensus
  • Negative Sentiment: Trading in put options rose sharply, with 6,604 puts bought—about 255% above average volume. This may reflect increased hedging or bearish positioning, though options activity alone does not determine the stock’s direction.

About GeneDx

(Get Free Report)

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

See Also

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.